Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera

BACKGROUND: Ruxolitinib, a Janus kinase (JAK) 1 and 2 inhibitor, was shown to have a clinical benefit in patients with polycythemia vera in a phase 2 study. We conducted a phase 3 open-label study to evaluate the efficacy and safety of ruxolitinib versus standard therapy in patients with polycythemi...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:N Engl J Med
Autori principali: Vannucchi, Alessandro M., Kiladjian, Jean Jacques, Griesshammer, Martin, Masszi, Tamas, Durrant, Simon, Passamonti, Francesco, Harrison, Claire N., Pane, Fabrizio, Zachee, Pierre, Mesa, Ruben, He, Shui, Jones, Mark M., Garrett, William, Li, Jingjin, Pirron, Ulrich, Habr, Dany, Verstovsek, Srdan
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2015
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4358820/
https://ncbi.nlm.nih.gov/pubmed/25629741
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1409002
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi